A representative for Karmelo Anthony has revealed that his family believes in his innocence in the Texas track meet stabbing ...

The family of Karmelo Anthony, the teenager who was charged with the murder of one of his peers, believes he’s innocent.

Karmelo Anthony's family has reportedly decided what to do with the more than $500,000 donated to their family. Anthony, a 17 ...

This week on Yahoo Finance Sports Report, host Joe Pompliano takes a look at some of this week's biggest headlines in the sports business world that you and your portfolio need to know. There are a ...

Advocacy group Next Generation Action Network says Karmelo Anthony is set to graduate but not walk after the family reached ...

The UTI Transportation & Logistics Fund Regular Plan Growth has an AUM of 3163.31 crores & has delivered CAGR of 29.96% in the last 5 years. The fund has an exit load of 1.00% and an expense ratio ...

The SBI Small Cap Fund Direct Plan Growth has an AUM of 31790.25 crores & has delivered CAGR of 31.36% in the last 5 years. The fund has an exit load of 1.00% and an expense ratio of 0.72%.

If sold after 1 year from purchase date, long term capital gain tax will be applicable. Current tax rate is 12.5%, if your total long term capital gain exceeds 1.25 lakh. Any cess/surcharge is not ...

If sold after 1 year from purchase date, long term capital gain tax will be applicable. Current tax rate is 12.5%, if your total long term capital gain exceeds 1.25 lakh. Any cess/surcharge is not ...

In a filing with the Securities and Exchange Commission, Centessa said it plans to use proceeds to fund the development of the 16 drugs in its pipeline, as well as potential acquisitions.

Timothy Plan Large/ Mid Cap Growth Fund earns a Below Average Process Pillar rating. The process benefits from the stability of the management team. Specifically, the fund has not seen a manager ...

In a filing with the US financial regulator Compass laid out its plans to develop the drug known as COMP360, which is a crystalline formulation of psilocybin in phase 2b clinical development in ...